Stem Cell Therapy Second Opinion: What to Check Before You Decide

Clinical insights from Prof. Dr. Serdar Kabataş, MD, PhD (C)

What a Stem Cell Therapy Second Opinion Should Actually Review

Patients sometimes send me two or three treatment proposals and ask a very simple question: “Which one is better?”

At first glance, it seems possible to compare them. One clinic offers 50 million cells, another 200 million. One recommends stem cells, another exosomes. Prices differ. The number of sessions differs. So do the routes of administration.

The problem is that these numbers can create a false sense of clarity. A higher cell count does not automatically mean a better treatment. A longer protocol is not necessarily a more advanced one. And a more expensive treatment is certainly not proof of better medical judgement.

When I look at such a proposal, I do not start with the price. I want to understand why this treatment was suggested in the first place. That is where I would advise patients to start as well.

This is also what I would expect from a stem cell therapy second opinion. It should not be a second price quote. It should be a second look at the medical reasoning behind the proposal.

1. Is Stem Cell Therapy Appropriate for Your Diagnosis?

Before asking how many cells are included, I would ask whether there is a good medical reason to use them at all. That sounds obvious, but in regenerative medicine it is not always handled that way.

A diagnosis alone tells us surprisingly little.

Two patients may both have multiple sclerosis and still be in completely different clinical situations. One may have active inflammatory disease. Another may mainly be dealing with long-standing neurological damage. The treatment question is not the same.

The same applies to spinal cord injury, osteoarthritis, ALS and many other conditions. What matters is the individual case.

• How old is the patient?
• How advanced is the disease?
• What is the current functional status?
• Which treatments have already been tried?
• Is the condition stable, progressive or fluctuating?

And then there are the investigations. In neurology, I may want to see MRI findings. In some patients, EMG or EEG results become relevant. In orthopedic cases, imaging often tells us far more than the diagnosis written on the first page of a report.

Sometimes, after reviewing these details, the conclusion is that regenerative treatment is not the right next step. That should also be an acceptable medical answer.

Not every patient who asks about stem cells is automatically a candidate for stem cells.

2. Who Actually Reviewed Your Medical Case?

I pay close attention to this.
Many proposals contain a sentence such as: “Your case has been approved by our medical team.”
But who exactly reviewed it?

• A physician?
• A coordinator?
• A general medical board?
• Someone from the specialty that actually treats the disease?

If a patient has ALS, I would expect a neurologically informed assessment. If the problem is a damaged knee, the orthopedic findings matter.

If there is a spinal condition, I want to understand whether there is compression, instability or another structural issue that may require a completely different approach.

The phrase “medical team” is not enough for me. The same applies when evaluating a stem cell clinic. The person responsible for the medical decision should be identifiable.

A patient should know the name or at least the specialty of the doctor who reviewed the case.
And there is another difference I consider important: collecting medical reports is not the same as evaluating them.
If a patient uploads an MRI report, someone should actually read what it says. If an EMG is relevant, it should be looked at. If there is previous surgery, that history may change the treatment plan.

This is not a detail. It is part of the treatment itself.

3. What Type of Stem Cells or Exosomes Are Being Offered?

“Stem cell therapy” is a broad term.

Patients often hear it as if it described one standard treatment. It does not.

Mesenchymal stromal cells can come from umbilical cord tissue, bone marrow or adipose tissue. Some treatments use autologous cells from the patient. Others use donor-derived, or allogeneic, cells.

These are not interchangeable products. They differ in source, preparation and biological characteristics.

Even the term “umbilical cord stem cells” can be confusing. MSCs obtained from umbilical cord tissue are not the same thing as hematopoietic stem cells from cord blood.

Then there are exosomes.

Exosomes are frequently mentioned in the same conversation, but they are not stem cells.

They are small extracellular vesicles released by cells. They carry biological signals and are being studied for their possible effects on inflammation, tissue repair and cell communication.

That research is interesting. It is also still developing.

Standardisation of exosome products remains an important issue, especially when comparing one clinic or laboratory with another.

So when patients ask me which source is “the best,” I usually cannot answer that question in isolation.

• Best for what?
• For which disease?
• For which biological purpose?
• In which patient?

Those questions have to come first.

4. Does a Higher Stem Cell Dose Mean a Better Treatment?

This is one of the comparisons I hear most often.
A patient receives two offers:

• Clinic A: 100 million cells.
• Clinic B: 300 million cells.

The natural assumption is that 300 million must be stronger.

But cells are not a medication where three tablets necessarily mean three times the dose effect. The biology is more complicated.

A cell number only makes sense when you know what kind of cells are being used, how viable they are, how they were manufactured, where they will be administered and for what indication.
Body weight may matter as well. So can the number of sessions.

Published trials do not use one universal MSC dose. They use very different protocols.

A 2026 systematic review looking at MSC dose and administration routes found wide variation between studies. Some used fixed doses. Others calculated dose by body weight. The authors did not identify a simple rule showing that higher numbers automatically produce better results.

That is consistent with what we already know from earlier clinical work: more cells are not necessarily better cells.

Sometimes a lower, well-defined dose in a carefully selected patient makes more sense than a very large number chosen mainly because it looks impressive in a treatment proposal.

Cell count matters. But without context, it is only a number.

5. How Were the Stem Cells Manufactured and Tested?

Once a cellular product is going to be administered to a patient, the laboratory becomes part of the treatment.

Patients often see the word “GMP” and assume that this answers every quality question. It does not.

GMP, or Good Manufacturing Practice, is important because it refers to controlled manufacturing processes. For cell-based products, this may include donor screening, isolation, expansion, microbiological controls, storage and batch release procedures.

But I would still want more detail.

• Was sterility tested?
• What was the viability?
• How was cell identity confirmed?
• Was the batch released according to defined criteria?
• Is there a Certificate of Analysis?

These are reasonable questions.

A vial may be labelled as containing a certain number of cells, but what ultimately matters is the quality of the product that reaches the patient.
There is another point worth separating.

A product can be manufactured under good laboratory conditions and still have limited evidence for a specific disease.
Manufacturing quality and clinical effectiveness are two different questions. Both need to be asked.

6. Why Were These Administration Routes Chosen?

The route of administration should make sense.

That may sound self-evident, yet many patients receive almost identical protocols despite having very different diagnoses.

IV plus intrathecal plus intranasal. Again and again.

I become cautious when the same combination appears to be used for nearly everyone.

• Intravenous administration has one biological distribution.
• An intra-articular injection is local and is mainly used when the target is a joint.
• Intrathecal administration brings the product into the cerebrospinal fluid. This is an invasive procedure and comes with different procedural considerations.
• Intranasal administration is being explored in neurological research, but the clinical evidence is still less standardised than many patients assume.

None of these routes is “better” in general.

The question is why that route was chosen for that patient. If there is no clear answer, I would want one before proceeding.

A complicated protocol is not automatically a sophisticated protocol.

7. What Does the Scientific Evidence for Stem Cell Therapy Really Show?

Almost every clinic today can show a patient a scientific paper. That by itself proves very little.
I want to know what kind of paper it is.

• Was it a mouse study?
• A small Phase I trial?
• A randomised controlled trial?
• How many patients were treated?
• Was there a control group?
• How long did follow-up last?

These details matter far more than the headline.
The evidence is also not equally strong across diseases.

Knee osteoarthritis has been studied in a considerable number of human MSC trials. Some studies report improvement in pain and function, although the quality and consistency of the evidence still vary.

ALS is different.
There are interesting early results from cell-based research, and this field deserves serious attention. But early evidence should not be translated into the statement that stem cells can cure ALS.

We are not there. The same caution is needed in autism spectrum disorder.
Small studies and early clinical trials exist, but patient numbers are limited and study designs differ considerably. At present, long-term effectiveness cannot be claimed with certainty.

This is an area where language matters. “Promising” does not mean “proven.”
“Improvement in one outcome measure” does not mean “cure.”

And a published study does not automatically mean that the exact treatment being offered by a clinic has been scientifically validated.

8. Are the Expected Results Realistic?

Patients usually come to regenerative medicine because they are looking for something conventional treatment has not been able to give them.

I understand that. But hope must not become a sales tool.
I would be very careful with statements such as:

• “You will walk again.”
• “Your child will start speaking.”
• “This treatment stops ALS.”
• “Your cartilage will regenerate completely.”

There are very few areas of medicine where such guarantees would be acceptable. In regenerative medicine, they are particularly problematic.

A realistic treatment discussion should explain what the actual goal is.
In one disease, the goal may be to reduce pain. In another, it may be to support function.
In a progressive neurological condition, even slowing deterioration could be clinically meaningful.

But slowing deterioration is not the same as reversing the disease. Improving one functional parameter is not the same as curing the condition.

Patients should know this before treatment starts.

9. What Should You Know About Stem Cell Therapy Safety and Treatment Alternatives?

Any serious treatment discussion must include risk. Not as a paragraph hidden at the end of a consent form. As part of the decision itself.

Risks depend on what is being administered and how.

An IV infusion does not have the same risk profile as an intrathecal procedure. A joint injection brings different considerations again.

Possible complications may include infection, infusion reactions, inflammatory responses and procedure-related problems.

Regulatory authorities and scientific organisations have repeatedly warned about poorly characterised or inadequately controlled regenerative products.

There is also a question that should never be forgotten: What are the alternatives?

• A patient with knee osteoarthritis may still have physiotherapy, weight management, injections or surgery as options.
• A patient with ALS still needs neurological care, respiratory monitoring, nutrition management and approved therapies.
• A patient with a spinal problem may need surgery rather than a biological treatment.

Regenerative medicine should not replace established treatment simply because it sounds more advanced.

Sometimes the correct recommendation is to continue conventional treatment. Sometimes it is to combine approaches. And sometimes it is not to proceed with regenerative treatment at all.

10. Stem Cell Therapy Cost: Compare the Whole Protocol, Not Just the Price

I understand why patients compare prices. Treatment can be expensive.
But USD 5,000 and USD 8,000 do not tell you very much until you know what is actually included.

A useful comparison should include:

• the medical assessment,
• the physician,
• the cell source,
• the manufacturing process,
• the cell dose,
• the route of administration,
• the treatment facility,
• the safety procedures,
• the scientific rationale,
• and the follow-up.

Only then does the price become meaningful.
The same applies to cell numbers.

“300 million cells” may sound convincing. But I would still ask:

• What cells?
• From where?
• How were they produced?
• How viable are they?
• Why 300 million?
• Why this route?
• Why for this patient?

Those questions tell me much more than the number itself.

Regenerative medicine is moving quickly. Some areas are genuinely promising. Others are still at an early stage.
Patients should not feel that they need to become stem cell scientists before making a decision. But they should expect clear answers.

And if an offer cannot be explained without relying mainly on big numbers, impressive terminology or promises, I would look at it very carefully.

Already Have a Stem Cell Treatment Proposal?

If you have already received a stem cell or exosome treatment proposal and would like a stem cell therapy second opinion, MedClinics can coordinate an individual medical case review with physicians experienced in regenerative medicine.

You can send your medical reports together with the treatment protocol you have already received. The proposed indication, cell product, dose, administration routes and overall treatment concept can then be reviewed in the context of your medical case.

Frequently Asked Questions About Stem Cell Therapy Second Opinion